A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma

Published:2023-06 Issue:3 Volume:6 Page:339-348
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

McGregor Bradley,Geynisman Daniel M.,Burotto Mauricio,Suárez Cristina,Bourlon Maria T.,Barata Pedro C.,Gulati Shuchi,Huo Stephen,Ejzykowicz Flavia,Blum Steven I.,Del Tejo Viviana,Hamilton Melissa,May Jessica R.,Du Ella X.,Wu Aozhou,Kral Pavol,Ivanescu Cristina,Chin Andi,Betts Keith A.,Lee Chung-Han,Choueiri Toni K.,Cella David,Porta Camillo

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference30 articles.

1. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2019

2. Renal cell carcinoma: diagnosis and management;Gray;Am Fam Physician,2019

3. Sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world and clinical trials data;Moran;Target Oncol,2019

4. Systemic therapy for metastatic renal-cell carcinoma;Choueiri;N Engl J Med,2017

5. Pazopanib versus sunitinib in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2013

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective;BMC Public Health;2024-02-12

2. Re: Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023;6:339–348;European Urology Oncology;2024-02

3. Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective;2023-10-02